MS is a chronic, progressive, inflammatory, and neurodegenerative disease of the central nervous system that leads to significant disability. The push towards ever earlier diagnosis and treatment of MS and the rapid emergence of novel agents are causing considerable changes to the management of the disease. The decisions regarding when to initiate treatment and which agents to use, along with deliberations on long-term management, are all increasingly difficult, with adherence issues continuing to negatively impact outcomes and add to the intricacy of MS treatment. The emerging data on biomarker research, aimed at increasing diagnostic accuracy and aiding in management, adds to the complexity of decision-making in MS. This program provides neurologists and MS specialists with updates on the latest advances in MS diagnosis and management, so that they can optimize outcomes for their patients with MS.
Faculty: SUHAYL DHIB-JALBUT, MD; CLYDE E. MARKOWITZ, MD; AARON E. MILLER, MD
Physicians: 1.25 AMA PRA Category 1 credit(s)™.
Nurses: 1.25 contact hours.
Visit the website
firstname.lastname@example.org or 303-395-1782